Janux Reports $970.9M Cash, Pipeline Progress in Q2 Update
JANX sits 31% above its 52-week low of $12.12.
Summary
Janux posted Q2 2026 results with $970.9M in cash, down slightly from $966.6M at year-end 2025. Net loss narrowed to $22.0M from $33.9M a year ago, driven by lower R&D spend. The pipeline update shows steady enrollment across prostate cancer programs JANX007 and JANX014, with a new combo cohort for JANX007 plus darolutamide. JANX011 in autoimmune disease is enrolling healthy volunteers, with initial data expected in the second half of 2026. JANX013, a PSMA-targeted costimulatory candidate, is on track to enter the clinic in the same timeframe. The cash position remains strong, but the update lacks clinical data or major catalysts — it's a routine quarterly check-in with no surprises.
At the time of this announcement, JANX was trading at $15.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $981.8M. The 52-week trading range was $12.12 to $35.34. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.